Benzosuberenes have highly potent anti-proliferative activity via inhibition of tubulin assembly at the colchicine binding site. Lead compounds include KGP18 and KGP156, which are potent small-molecule tubulin depolymerizing agents displaying sub-nanomolar (in the case of KGP18) antiproliferative activity in vitro against a number of human cancer cell lines. These compounds have also been shown to disrupt capillary-like networks of endothelial cells in vitro and induce reductions in tumor blood flow in human tumor xenografts in mice. Two publications detailing the synthesis and in vitro activity of the initial lead compounds in this series of benzosuberenes have appeared in print ( Bioorg. Med. Chem. 16:8161-8171 (2008); and Med. Chem. Commun. 3:720-24 (2012).


OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The Company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at


Baylor University is a private Christian university and a nationally ranked research institution, characterized as having "high research activity" by the Carnegie Foundation for the Advancement of Teaching. The university provides a vibrant campus community for approximately 15,000 students by blending interdisciplinary research with an international reputation for educational excellence and a faculty commitment to teaching and scholarship. Chartered in 1845 by the Republic of Texas through the efforts of Baptist pioneers, Baylor is the oldest continually operating university in Texas. Located in Waco, Baylor welcomes students from all 50 states and more than 80 countries to study a broad range of degrees among its 11 nationally recognized academic divisions. Baylor sponsors 19 varsity athletic teams and is a founding member of the Big 12 Conference.

If you liked this article you might like

OXiGENE (OXGN) Stock Gains on Positive FDA Feedback for Cancer Treatment Trials

Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta

Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data

Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta

3 Biotech Stocks Under $10 in Breakout Territory